Stock Code: 002399 Stock Abbreviation: Hepalink Announcement No.: 2026-020
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Resolution Announcement of the 21st Meeting of the 6th Board of Directors
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or significant omissions.
I. Convening of the Board Meeting
The notice and proposals for the 21st meeting of the 6th Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") were sent via email on April 16, 2026. The meeting was held on April 29, 2026, at 14:00 in the conference room at Langshan Road 21, Songpingshan, Nanshan District, Shenzhen, through a combination of on-site and teleconference methods. A total of 7 directors were eligible to vote, and 7 directors actually participated in the voting. Among them, Mr. Zhang Ping, Mr. Huang Peng, Mr. Yi Ming, and Mr. Pu Hong participated via teleconference. Senior management personnel of the Company attended the meeting, which was presided over by Mr. Li Ning, Chairman of the Board. The notice, convening, and number of participating directors in this meeting comply with relevant laws, regulations, and the "Articles of Association" of the Company.
II. Deliberation of the Board Meeting
After careful deliberation by the attending directors, the following proposals were reviewed and approved:
- "Q1 2026 Report" and "Q1 2026 Performance Announcement" (H Shares) Voting results: 7 votes in favor, 0 abstentions, 0 against. The specific content can be found in the "Q1 2025 Report" disclosed on the same day in "Securities Times," "China Securities Journal," "Shanghai Securities News," "Securities Daily," and cninfo.com.cn; and the H Share "Q1 2026 Performance Announcement" disclosed on the same day on the website of the Stock Exchange of Hong Kong Limited www.hkexnews.hk and the Company's website www.hepalink.com. This proposal has been unanimously approved by the 14th meeting of the Audit Committee of the 6th Board of Directors of the Company.